FeesSafety
Pluang+

Bushido Capital US Equity ETF retains Hold rating despite portfolio changes and mixed past performance.

Analyst Insights
17 Nov 2026, 11:05 WIB
Seeking Alpha
View Source
Neutral
Bushido Capital US Equity ETF retains Hold rating despite portfolio changes and mixed past performance.

The Bushido Capital US Equity ETF (SMRI) maintains a Hold rating after replacing about 30% of its holdings since August, enhancing its growth at a reasonable price (GARP) and quality traits. However, concerns remain due to its concentrated portfolio, inconsistent past alpha, and weaker quantitative and Wall Street ratings compared to the IVV benchmark. Despite these issues, SMRI is considered a viable option for investors seeking active strategies focused on free cash flow. The analyst emphasizes cautious optimism rather than outright bullishness.

The Bushido Capital US Equity ETF (SMRI) is the subject, with Pluang market data providing context as of Nov 17, 2026 14:11 WIB. Of 150 priced US stocks tradable on Pluang, 33 rose and 112 fell today. Notable movers include CVE at USD 28.10 with a 1-day change of -3.37%, BABA at USD 87.59 down 3.34%, and PTON at USD 5.16 down 3.19%.

More News

Atos secures contract to manage and unify France's shared medical records platform with Mon Espace Santé.

Atos secures contract to manage and unify France's shared medical records platform with Mon Espace Santé.

Atos has been selected by France's Caisse nationale de l’Assurance Maladie (Cnam) to manage and secure the Dossier Médical Partagé (DMP) and integrate it with Mon Espace Santé (MES) into a unified digital health platform. This platform, serving over ...

Market News
Bullish
28 minutes ago
Atos completes integration of France's Shared Medical Record with Mon Espace Santé platform

Atos completes integration of France's Shared Medical Record with Mon Espace Santé platform

Atos has successfully transitioned and integrated France's Shared Medical Record (DMP) with the Mon Espace Santé (MES) platform, creating a unified, secure digital health infrastructure for over 60 million insured people. This integration supports th...

Market News
Bullish
28 minutes ago
Commit Biologics raises $60M seed round to advance novel immune therapy for cancer and autoimmune diseases

Commit Biologics raises $60M seed round to advance novel immune therapy for cancer and autoimmune diseases

Commit Biologics secured $60 million in seed funding led by Ackermans & van Haaren with participation from AbbVie Ventures, M Ventures, and others. The funds will support clinical development of COM002, a first-in-class immune engager targeting cance...

Company Fundamentals
Bullish
3 hours ago
Dassault Systèmes targets double-digit revenue and EPS growth by 2029 with AI-driven industrial solutions.

Dassault Systèmes targets double-digit revenue and EPS growth by 2029 with AI-driven industrial solutions.

Dassault Systèmes announced at its 2026 Capital Markets Day a new growth cycle aiming for double-digit revenue and EPS growth by 2029, targeting over €8 billion in revenue and €1.80 in non-IFRS diluted EPS. The company highlights its transition to su...

Market News
Bullish
3 hours ago
Dassault Systèmes targets double-digit revenue and EPS growth by 2029, driven by AI and subscription model.

Dassault Systèmes targets double-digit revenue and EPS growth by 2029, driven by AI and subscription model.

Dassault Systèmes announced a new growth cycle aiming for double-digit increases in revenue and diluted EPS by 2029, with revenue expected to exceed €8 billion and EPS €1.80. This growth is supported by a strong subscription model, accelerating adopt...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App